# Immunology & Immunotherapy of Cancer Research Program (Project-006)

> **NIH NIH P30** · STANFORD UNIVERSITY · 2020 · $43,892

## Abstract

PROGRAM SUMMARY – IMMUNOLOGY AND IMMUNOTHERAPY PROGRAM 
The Immunology and Immunotherapy of Cancer Program (IM) represents a merger of the former Cancer 
Immunology and Immunotherapy and the Hematopoietic Cell Transplantation and Immune Reconstitution 
Programs that took place with the approval of the External Advisory Board in 2012. The major overall goals 
of the program are to understand the nature of the immune system and its response to malignancies and to 
explore auto- and allo-immune responses to cancer with the goal of enabling the discovery and 
development of more effective anti-tumor immunotherapy. These goals will be achieved by fostering 
collaborative research, advancing the latest technologies to probe immunological mechanisms, and by 
enhancing the infrastructure for clinical translation. Research by program members has resulted in exciting 
new developments in both understanding immune function and developing novel therapies. Advances 
include the development and application of CyTOF and high throughput sequencing for evaluating cellular 
function and responses and the translation of important concepts to the clinic in promising early phase 
clinical trials 
Co-led by Robert Negrin, MD and Edgar Engleman, MD, the 32 members of the program represent nine 
departments in the School of Medicine. Program members are major participants in one NCI P01, a number 
of NCI R01s, R21 and R33 and a NIH T32. Peer-reviewed funding is represented by a total of $12.2M in 
total costs/year of which $2.4M is from the NCI, $5.5M from other NIH Institutes, and $4.4M from other 
peer-reviewed sources. During the past five years, over 300 papers have been published, of which 22% are 
intra-programmatic and 32% inter-programmatic. Many of these manuscripts reflect external collaborations. 
Future aims include the use of new technologies to analyze the immune responses to tumors and the 
development of novel cellular therapeutic and other immunological interventions including CD8+ memory T 
cells, cytokine-induced killer (CIK) cells, CAR T cells and other genetically engineered cellular and biological 
therapies.

## Key facts

- **NIH application ID:** 9936165
- **Project number:** 5P30CA124435-13
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Robert S Negrin
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $43,892
- **Award type:** 5
- **Project period:** — → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9936165

## Citation

> US National Institutes of Health, RePORTER application 9936165, Immunology & Immunotherapy of Cancer Research Program (Project-006) (5P30CA124435-13). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9936165. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*